NASDAQ:PSTI - Pluristem Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.17
  • Forecasted Upside: 234.55 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.74
▼ -0.25 (-8.36%)

This chart shows the closing price for PSTI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pluristem Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PSTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PSTI

Analyst Price Target is $9.17
▲ +234.55% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Pluristem Therapeutics in the last 3 months. The average price target is $9.17, with a high forecast of $12.50 and a low forecast of $6.00. The average price target represents a 234.55% upside from the last price of $2.74.

This chart shows the closing price for PSTI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Pluristem Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/4/2021Alliance Global PartnersInitiated CoverageBuy$12.50Low
12/10/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$6.00High
12/7/2020HC WainwrightReiterated RatingBuy$15.50 ➝ $9.00High
10/9/2020Dawson JamesReiterated RatingBuy$12.00Low
7/24/2020Jefferies Financial GroupBoost Price TargetBuy$12.00 ➝ $16.00Medium
6/19/2020Jefferies Financial GroupInitiated CoverageBuy$12.00High
5/15/2020Maxim GroupReiterated RatingBuy$12.00Low
5/14/2020HC WainwrightReiterated RatingBuy$15.50Medium
4/15/2020Dawson JamesReiterated RatingBuyHigh
4/14/2020Maxim GroupInitiated CoverageBuy$12.00High
4/8/2020Maxim GroupInitiated CoverageBuy$8.00High
3/31/2020Maxim GroupInitiated CoverageBuy$8.00Medium
3/18/2020Maxim GroupReiterated RatingBuy$8.00High
2/10/2020HC WainwrightReiterated RatingBuy$15.50Low
12/16/2019Dawson JamesInitiated CoverageBuy$12.00High
12/4/2019Maxim GroupReiterated RatingBuy$8.00Low
11/13/2019Maxim GroupReiterated RatingBuy$8.00High
11/13/2019HC WainwrightReiterated RatingBuy$15.50High
7/22/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ BuyLow
4/24/2019Maxim GroupReiterated RatingBuy$30.00Low
12/17/2018Maxim GroupSet Price TargetBuy$30.00Medium
12/17/2018HC WainwrightSet Price TargetBuy$40.00Medium
12/4/2018Maxim GroupSet Price TargetBuy$30.00High
11/28/2018Maxim GroupReiterated RatingBuy$30.00High
11/12/2018HC WainwrightSet Price TargetBuy$40.00Low
9/28/2018HC WainwrightReiterated RatingBuy$35.00Low
7/31/2018B. RileyInitiated CoverageBuy$45.00Low
5/11/2018HC WainwrightSet Price TargetBuy$40.00High
5/10/2018Maxim GroupSet Price TargetBuy$30.00Low
5/1/2018HC WainwrightSet Price TargetBuy$40.00Medium
4/30/2018Maxim GroupSet Price TargetBuy$30.00High
4/23/2018Maxim GroupReiterated RatingBuy$30.00Low
2/21/2018Maxim GroupSet Price TargetBuy$30.00Medium
1/16/2018HC WainwrightSet Price TargetBuy$40.00Medium
11/9/2017HC WainwrightReiterated RatingBuy$35.00N/A
11/1/2017Maxim GroupSet Price TargetBuy$30.00N/A
10/26/2017Maxim GroupSet Price TargetBuy$30.00N/A
10/19/2017Maxim GroupSet Price TargetBuy$20.00N/A
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$50.00N/A
10/2/2017Maxim GroupSet Price TargetBuy$20.00Low
9/19/2017HC WainwrightReiterated RatingBuy$35.00Low
9/6/2017HC WainwrightReiterated RatingBuy$35.00Medium
9/5/2017Maxim GroupReiterated RatingBuy$20.00Medium
8/17/2017HC WainwrightSet Price TargetBuy$40.00Medium
8/16/2017Maxim GroupSet Price TargetBuy$20.00Medium
7/10/2017Maxim GroupSet Price TargetBuy$20.00High
6/19/2017Maxim GroupUpgradeHold ➝ Buy$20.00Low
5/22/2017Maxim GroupReiterated RatingHoldLow
5/15/2017HC WainwrightReiterated RatingBuy$35.00Low
5/5/2017HC WainwrightReiterated RatingBuy$35.00Low
5/4/2017Maxim GroupReiterated RatingHoldLow
2/13/2017Maxim GroupDowngradeBuy ➝ HoldN/A
2/11/2017HC WainwrightSet Price TargetBuy$40.00N/A
1/17/2017Maxim GroupSet Price TargetBuy$30.00N/A
1/10/2017FBR & Co.Reiterated RatingBuyN/A
12/23/2016FBR & Co.Reiterated RatingOutperform$60.00N/A
11/2/2016Maxim GroupSet Price TargetBuy$30.00N/A
(Data available from 10/23/2016 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2021

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Pluristem Therapeutics logo
Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Read More

Today's Range

Now: $2.74
Low: $2.67
High: $2.97

50 Day Range

MA: $2.88
Low: $2.46
High: $3.26

52 Week Range

Now: $2.74
Low: $2.44
High: $11.85

Volume

245,655 shs

Average Volume

445,433 shs

Market Capitalization

$87.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Pluristem Therapeutics?

The following Wall Street analysts have issued stock ratings on Pluristem Therapeutics in the last twelve months: Alliance Global Partners, HC Wainwright, Jefferies Financial Group Inc., and Zacks Investment Research.
View the latest analyst ratings for PSTI.

What is the current price target for Pluristem Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Pluristem Therapeutics in the last year. Their average twelve-month price target is $9.17, suggesting a possible upside of 234.5%. Alliance Global Partners has the highest price target set, predicting PSTI will reach $12.50 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $6.00 for Pluristem Therapeutics in the next year.
View the latest price targets for PSTI.

What is the current consensus analyst rating for Pluristem Therapeutics?

Pluristem Therapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PSTI will outperform the market and that investors should add to their positions of Pluristem Therapeutics.
View the latest ratings for PSTI.

How do I contact Pluristem Therapeutics' investor relations team?

Pluristem Therapeutics' physical mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The biotechnology company's listed phone number is 972747107171 and its investor relations email address is [email protected] The official website for Pluristem Therapeutics is www.pluristem.com.